Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Fairlie

Showing results (21-30 of 326) with videos related to

Pageof 33
Sort By:
Current Drug Targets|June 6, 2012
Targeting quorum sensing and competence stimulation for antimicrobial chemotherapyNicholas E Shepherd, Rosemary S Harrison, David P Fairlie
Molecular Neurodegeneration|July 24, 2019
Alpha-synuclein structure and Parkinson's disease - lessons and emerging principlesRichard M Meade, David P Fairlie, Jody M Mason
Current Medicinal Chemistry|February 16, 2006
Agonists and antagonists of protease activated receptors (PARs)Grant D Barry, Giang T Le, David P Fairlie
Current Pharmaceutical Design|May 22, 2012
Towards histone deacetylase inhibitors as new antimalarial drugsKatherine T Andrews, Thanh N Tran, David P Fairlie
Angewandte Chemie (International Ed. in English)|November 13, 2020
Connecting Hydrophobic Surfaces in Cyclic Peptides Increases Membrane PermeabilityHuy N Hoang, Timothy A Hill, David P Fairlie
Expert Opinion on Therapeutic Patents|March 4, 2016
Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015)Mei-Kwan Yau, Junxian Lim, Ligong Liu, et al.
Journal of Cell Communication and Signaling|November 22, 2023
Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cellsHimani Shah, Timothy A Hill, Junxian Lim, et al.
Chemical Biology & Drug Design|December 21, 2012
The future of peptide-based drugsDavid J Craik, David P Fairlie, Spiros Liras, et al.
Plos One|November 13, 2010
Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cellsJacky Y Suen, Brooke Gardiner, Sean Grimmond, et al.
Journal of Medicinal Chemistry|October 5, 2017
Chemical Approaches to Modulating Complement-Mediated DiseasesAbishek Iyer, Weijun Xu, Robert C Reid, et al.
Pageof 33

Showing results (21-30 of 326) with videos related to

Sort By:
Pageof 33
Current Drug Targets|June 6, 2012
Targeting quorum sensing and competence stimulation for antimicrobial chemotherapyNicholas E Shepherd, Rosemary S Harrison, David P Fairlie
Molecular Neurodegeneration|July 24, 2019
Alpha-synuclein structure and Parkinson's disease - lessons and emerging principlesRichard M Meade, David P Fairlie, Jody M Mason
Current Medicinal Chemistry|February 16, 2006
Agonists and antagonists of protease activated receptors (PARs)Grant D Barry, Giang T Le, David P Fairlie
Current Pharmaceutical Design|May 22, 2012
Towards histone deacetylase inhibitors as new antimalarial drugsKatherine T Andrews, Thanh N Tran, David P Fairlie
Angewandte Chemie (International Ed. in English)|November 13, 2020
Connecting Hydrophobic Surfaces in Cyclic Peptides Increases Membrane PermeabilityHuy N Hoang, Timothy A Hill, David P Fairlie
Expert Opinion on Therapeutic Patents|March 4, 2016
Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015)Mei-Kwan Yau, Junxian Lim, Ligong Liu, et al.
Journal of Cell Communication and Signaling|November 22, 2023
Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cellsHimani Shah, Timothy A Hill, Junxian Lim, et al.
Chemical Biology & Drug Design|December 21, 2012
The future of peptide-based drugsDavid J Craik, David P Fairlie, Spiros Liras, et al.
Plos One|November 13, 2010
Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cellsJacky Y Suen, Brooke Gardiner, Sean Grimmond, et al.
Journal of Medicinal Chemistry|October 5, 2017
Chemical Approaches to Modulating Complement-Mediated DiseasesAbishek Iyer, Weijun Xu, Robert C Reid, et al.
Pageof 33